SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Surrozen, Inc./DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$23.84+0.40 (+1.71%)
Close on Oct 19, 2026
- Market cap
- $551.80M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-1210.6%
Net margin
-6960.8%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -67.4% | -34.7% | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -85.3% | 231.4% | |
| Return on assets | – | – | -328.9% | |
| Current ratio | – | 6.90 | 9.22 | |
| Capex to revenue | – | – | 3.7% | |
| Diluted shares | – | 1M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Surrozen generated $181.19M from operations and spent $5.16M on capital expenditure, dividends and share buybacks. 49% of that went back into the business.
Generated
$181.19M
Used
$5.16M
Capital expenditure$2.55M49%Dividends$00%Share buybacks$2.61M51%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-6960.8%
×Asset turnover0.05×
×Equity multiplier-0.70×
=Return on equity, FY2025231.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -6960.8% | 0.05× | -0.70× | 231.4% |
| FY2024 | -596.6% | 0.23× | 5.71× | -767.9% |
| FY2022 | -288.0% | 0.11× | 1.22× | -38.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$242.03M
- Cash generatingOperating cash flow above zero-$30.24M
- Return on assets improvedROA up on the prior year-137.9% → -499.4%
- Earnings backed by cashOperating cash flow above net income-$30.24M vs -$242.03M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.32 → 9.22
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.23 → 0.07